TIBER CREEK GROUP

Lobbying for MERCK & CO., INC · Prescription medicines, vaccines, and biologic therapies

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 21, 2025

Lobbying activity 2

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform.

Trade (domestic/foreign)

Issues related to intellectual property protections.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.